Description
Structure & Identity
The kit contains distinct components. Semaglutide is a modified GLP-1 receptor agonist (CAS 910463-68-2). Each blend vial contains CJC-1295 (no DAC / Modified GRF 1-29), a GHRH analog, plus ipamorelin, a selective growth-hormone secretagogue (CAS 170851-70-4). Each keeps its own structure and receptor target.
Research Background
The kit spans metabolic and growth-hormone-axis research.
- GLP-1 signaling. Semaglutide is a GLP-1 receptor agonist studied in metabolic research [PMID: 34626851].
- GLP-1 mechanism. GLP-1-based signaling mechanisms are an active area [PMID: 40466247].
- GHRH arm. CJC-1295 acts at the GHRH receptor for GH/IGF-1 stimulation [PMID: 16352683].
- Ghrelin arm. Ipamorelin is a selective GH secretagogue [PMID: 9849822].
- Combined rationale. The kit spans metabolic and growth-hormone-axis research.
These are research contexts, not approved uses, and the kit is intended for laboratory study.
Specifications
| Attribute | Value |
| Product type | Kit (three vials) |
| Vial 1 | Semaglutide (GLP-1 agonist), 5 mg (CAS 910463-68-2) |
| Vials 2-3 | CJC-1295 (no DAC) / Ipamorelin blend, 5 mg / 5 mg each |
| Purity | ≥99% by reverse-phase HPLC (each) |
| Identity | Confirmed by ESI mass spectrometry |
| Physical form | Lyophilized powder |
| Storage | -20°C, protected from light |
| Solubility | Soluble in bacteriostatic or sterile water |
| Classification | Research use only |
Storage & Handling
Keep all sealed vials frozen at -20°C and shielded from light until use. After preparing for your assay, store each solution at 2-8°C and use it in your study within about two weeks. Warm a vial to room temperature before opening, and avoid repeated freeze-thaw cycles so each peptide stays intact.
Quality Assurance
The components of this kit are produced under research-grade manufacturing controls and verified by an independent lab before release. Purity is measured by reverse-phase HPLC and identity by mass spectrometry, with testing carried out by third-party laboratories, including Janoshik Analytical and domestic US labs. Each vial ships with its own batch-specific certificate of analysis.
Frequently Asked Questions
What is in this kit?
Three vials: one Semaglutide 5 mg, plus two vials of a CJC-1295 (no DAC)/Ipamorelin 5/5 mg blend. The kit is studied across metabolic and growth-hormone-axis research and supplied for research use only.
Which CJC-1295 is included, DAC or no DAC?
The no-DAC form (Modified GRF 1-29), a shorter-acting GHRH analog. It is combined with ipamorelin in each blend vial.
Why combine a GLP-1 peptide with GH-axis peptides?
It brings metabolic-signaling research (Semaglutide) together with growth-hormone-axis research (CJC-1295 and ipamorelin) in one set.
Are the peptides combined in one vial?
Semaglutide is its own vial; CJC-1295 and ipamorelin are pre-combined in each of the two blend vials. So the kit has three vials total.
Is this kit FDA approved?
This kit is a research-use-only preparation. It is not equivalent to, and not a substitute for, any FDA-approved product, and it is not for human or veterinary use.
Does each vial come with its own COA?
Yes, each vial is tested and publishes its own batch-specific certificate of analysis.
How should the kit be stored?
Keep all powders frozen at -20°C and protected from light until use. As with all lyophilized peptides, preparation and post-preparation handling should follow your lab’s own protocols
How are the components verified?
Each is tested to ≥99% purity by reverse-phase HPLC with mass-spec identity confirmation by an independent lab.
